The purpose of this study is to assess the kinetics of antibodies against SARS-CoV-2 as well as the kinetics of the immune system's cell subpopulations and cytokines associated with the immune system in healthy volunteers receiving the BNT162b2 vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies or any other vaccine authorized and administered by the Ministry of Health. Immunoassays will be performed at serum collection points before and after vaccination, as set out in this study.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy volunteers and all individuals who, according to the instructions of the Greek State are considered eligible to receive the BNT162b2 vaccine
Age ≥ 18 years old
You may not be if
Serious allergy problems i.e. hospitalization due to a serious allergic reaction (anaphylaxis)
